

Kapsch TrafficCom Holding Corp.,  
8201 Greensboro Drive, Suite 1002,  
McLean, VA 22102.

Kapsch TrafficCom Canada, Inc., 6020  
Ambler Drive, Mississauga, ON L4W  
2P1, Canada.

Star Systems International, Ltd., Unit  
A01, 24/F Gold King Industrial  
Building, 35–41 Tai Lin Pai Road, Kwai  
Chung, Hong Kong.

STAR RFID Co., Ltd., 1 Charoenrat  
Road, Thung Wat Don, Sathon, Bangkok  
10120 Thailand.

(c) The Office of Unfair Import  
Investigations, U.S. International Trade  
Commission, 500 E Street SW., Suite  
401, Washington, DC 20436;

(3) Pursuant to Commission Rule  
210.50(b)(1), 19 CFR 210.50(b)(1), the  
presiding administrative law judge shall  
take evidence or other information and  
hear arguments from the parties and  
other interested persons with respect to  
the public interest in this investigation,  
as appropriate, and provide the  
Commission with findings of fact and a  
recommended determination on this  
issue, which shall be limited to the  
statutory public interest factors set forth  
in 19 U.S.C. 1337(d)(1), (f)(1), (g)(1);

(4) For the investigation so instituted,  
the Chief Administrative Law Judge,  
U.S. International Trade Commission,  
shall designate the presiding  
Administrative Law Judge.

Responses to the complaint and the  
notice of investigation must be  
submitted by the named respondents in  
accordance with section 210.13 of the  
Commission's Rules of Practice and  
Procedure, 19 CFR 210.13. Pursuant to  
19 CFR 201.16(e) and 210.13(a), such  
responses will be considered by the  
Commission if received not later than 20  
days after the date of service by the  
Commission of the complaint and the  
notice of investigation. Extensions of  
time for submitting responses to the  
complaint and the notice of  
investigation will not be granted unless  
good cause therefor is shown.

Failure of a respondent to file a timely  
response to each allegation in the  
complaint and in this notice may be  
deemed to constitute a waiver of the  
right to appear and contest the  
allegations of the complaint and this  
notice, and to authorize the  
administrative law judge and the  
Commission, without further notice to  
the respondent, to find the facts to be as  
alleged in the complaint and this notice  
and to enter an initial determination  
and a final determination containing  
such findings, and may result in the  
issuance of an exclusion order or a cease  
and desist order or both directed against  
the respondent.

By order of the Commission.

Issued: January 6, 2016.

**Lisa R. Barton,**

*Secretary to the Commission.*

[FR Doc. 2016–00289 Filed 1–8–16; 8:45 am]

**BILLING CODE 7020–02–P**

## DEPARTMENT OF JUSTICE

### Antitrust Division

#### Notice Pursuant to the National Cooperative Research and Production Act of 1993—R Consortium, Inc.

Notice is hereby given that, on  
December 3, 2015, pursuant to section  
6(a) of the National Cooperative  
Research and Production Act of 1993,  
15 U.S.C. 4301 *et seq.* (“the Act”), R  
Consortium, Inc. (“R Consortium”) has  
filed written notifications  
simultaneously with the Attorney  
General and the Federal Trade  
Commission disclosing changes in its  
membership. The notifications were  
filed for the purpose of extending the  
Act's provisions limiting the recovery of  
antitrust plaintiffs to actual damages  
under specified circumstances.  
Specifically, 0965688 BC LTD., Surrey,  
British Columbia, CANADA, has been  
added as a party to this venture.

No other changes have been made in  
either the membership or planned  
activity of the group research project.  
Membership in this group research  
project remains open, and R Consortium  
intends to file additional written  
notifications disclosing all changes in  
membership.

On September 15, 2015, R Consortium  
filed its original notification pursuant to  
section 6(a) of the Act. The Department  
of Justice published a notice in the  
**Federal Register** pursuant to section  
6(b) of the Act on October 2, 2015 (80  
FR 59815).

**Patricia A. Brink,**

*Director of Civil Enforcement, Antitrust  
Division.*

[FR Doc. 2016–00323 Filed 1–8–16; 8:45 am]

**BILLING CODE P**

## DEPARTMENT OF JUSTICE

### Antitrust Division

#### Notice Pursuant to the National Cooperative Research and Production Act of 1993—The Open Group, L.L.C.

Notice is hereby given that, on  
December 8, 2015, pursuant to section  
6(a) of the National Cooperative  
Research and Production Act of 1993,  
15 U.S.C. 4301 *et seq.* (“the Act”), The  
Open Group, L.L.C. (“TOG”) has filed

written notifications simultaneously  
with the Attorney General and the  
Federal Trade Commission disclosing  
changes in its membership. The  
notifications were filed for the purpose  
of extending the Act's provisions  
limiting the recovery of antitrust  
plaintiffs to actual damages under  
specified circumstances.

Specifically, AEGIS.net, Inc.,  
Rockville, MD; Air Force Research  
Laboratory, Kirtland AFB, NM; Aoyama  
Gakuin University, Tokyo, JAPAN; Bank  
of Zambia, Lusaka, ZAMBIA; Dunstan  
Thomas Consulting, Ltd., Portsmouth,  
UNITED KINGDOM; Front Metrics  
Technologies Pvt. Ltd., Pune, INDIA;  
Geco, Inc., Mesa, AZ; Inspur Co., Ltd.,  
Beijing, PEOPLE'S REPUBLIC OF  
CHINA; IAB BVBA, Boutersem,  
BELGIUM; Intelligent Training de  
Columbia, Bogota, COLOMBIA; Joint  
Tactical Network Center, San Diego, CA;  
M J Anniss, Ltd., Nairn, UNITED  
KINGDOM; PLANAD Consultoria em  
Gestão Empresarial Ltda., São Paulo,  
BRAZIL; SIGMAXYZ Inc., Tokyo,  
JAPAN; S.P. Jain Institute of  
Management Research, Mumbai, INDIA;  
Universidad Continental, Huancayo,  
PERU; University of Dayton Research  
Institute, Dayton, OH; Vencore, Inc.,  
Lexington Park, MD; Vigilance, Inc.,  
McLean, VA; and White Cloud Software  
Ltd., Bowen Island, CANADA, have  
been added as parties to this venture.

Also, Architecture Capability  
Assurance Strategic Group, Palo Alto,  
CA; ATSI S.A., Zabierzow, POLAND;  
AXE, Inc., Nakagyo-ku, JAPAN; Bell  
Helicopter Textron Inc., Fort Worth, TX;  
CS Interactive Training, Pretoria,  
SOUTH AFRICA; EXELIS, Inc., Clifton,  
NJ; Fairchild Controls Corporation,  
Frederick, MD; Hoople Limited,  
Hereford, UNITED KINGDOM; Howell  
Instruments, Inc., Fort Worth, TX; Indra  
Colombia, Bogota, COLOMBIA;  
Kamehameha Schools-Trustees of the  
Estate of Bernice Pauahi Bishop,  
Honolulu, HI; Korea Software  
Technology Association, Gyeonggi-Do,  
REPUBLIC OF KOREA; Mobile  
Reasoning, Inc., Lenaxa, KS; Nippon  
Telegraph & Telephone Corporation,  
Tokyo, JAPAN; Online Business  
Systems, Winnepeg, CANADA;  
PreterLex Limited, Cambridge, UNITED  
KINGDOM; University of Nordland,  
Oslo, NORWAY; VIP Apps Consulting  
Limited, Hertfordshire, UNITED  
KINGDOM; and World Vision  
International, Monrovia, CA, have  
withdrawn as parties to this venture.

In addition, Hewlett Packard  
Company has changed its name to  
Hewlett Packard Enterprises, Cupertino,  
CA.

No other changes have been made in either the membership or planned activity of the group research project. Membership in this group research project remains open, and TOG intends to file additional written notifications disclosing all changes in membership.

On April 21, 1997, TOG filed its original notification pursuant to section 6(a) of the Act. The Department of Justice published a notice in the **Federal Register** pursuant to section 6(b) of the Act on June 13, 1997 (62 FR 32371).

The last notification was filed with the Department on September 9, 2015. A notice was published in the **Federal Register** pursuant to section 6(b) of the Act on October 2, 2015 (80 FR 59816).

**Patricia A. Brink,**

*Director of Civil Enforcement, Antitrust Division.*

[FR Doc. 2016-00325 Filed 1-8-16; 8:45 am]

**BILLING CODE P**

**DEPARTMENT OF JUSTICE**

**Drug Enforcement Administration**

[Docket No. DEA-392]

**Importer of Controlled Substances Application: Sharp Clinical Services, Inc.**

**ACTION:** Notice of application.

**DATES:** Registered bulk manufacturers of the affected basic class, and applicants therefore, may file written comments on or objections to the issuance of the proposed registration in accordance with 21 CFR 1301.34(a) on or before February 10, 2016. Such persons may also file a written request for a hearing on the application pursuant to 21 CFR 1301.43 on or before February 10, 2016.

**ADDRESSES:** Written comments should be sent to: Drug Enforcement Administration, Attention: DEA **Federal Register** Representative/ODW, 8701 Morrisette Drive, Springfield, Virginia 22152. Request for hearings should be sent to: Drug Enforcement Administration, Attention: Hearing Clerk/LJ, 8701 Morrisette Drive, Springfield, Virginia 22152.

**SUPPLEMENTARY INFORMATION:** The Attorney General has delegated her authority under the Controlled Substances Act to the Administrator of the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority to exercise all necessary functions with respect to the promulgation and implementation of 21 CFR part 1301, incident to the registration of manufacturers, distributors, dispensers, importers, and exporters of controlled

substances (other than final orders in connection with suspension, denial, or revocation of registration) has been redelegated to the Deputy Assistant Administrator of the DEA Office of Diversion Control (“Deputy Assistant Administrator”) pursuant to section 7 of 28 CFR part 0, appendix to subpart R.

In accordance with 21 CFR 1301.34(a), this is notice that on July 29, 2015, Sharp Clinical Services, Inc., 300 Kimberton Road, Phoenixville, Pennsylvania 19460 applied to be registered as an importer of marihuana (7360), a basic class of controlled substance listed in schedule I.

The company plans to import finished pharmaceutical products containing cannabis extracts in dosage form for clinical trial studies.

This compound is listed under drug code 7360. No other activity for this drug code is authorized for this registration. Approval of permits applications will occur only when the registrant’s business activity is consistent with what is authorized under 21 U.S.C. 952(a)(2). Authorization will not extend to the import of FDA approved or non-approved finished dosage forms for commercial sale.

Dated: January 4, 2016.

**Louis J. Milione,**

*Deputy Assistant Administrator.*

[FR Doc. 2016-00214 Filed 1-8-16; 8:45 am]

**BILLING CODE 4410-09-P**

**DEPARTMENT OF JUSTICE**

**Drug Enforcement Administration**

[Docket No. DEA-392]

**Importer of Controlled Substances Application: Myoderm**

**ACTION:** Notice of application.

**DATES:** Registered bulk manufacturers of the affected basic classes, and applicants therefore, may file written comments on or objections to the issuance of the proposed registration in accordance with 21 CFR 1301.34(a) on or before February 10, 2016. Such persons may also file a written request for a hearing on the application pursuant to 21 CFR 1301.43 on or before February 10, 2016.

**ADDRESSES:** Written comments should be sent to: Drug Enforcement Administration, Attention: DEA **Federal Register** Representative/ODW, 8701 Morrisette Drive, Springfield, Virginia 22152. Request for hearings should be sent to: Drug Enforcement Administration, Attention: Hearing

Clerk/LJ, 8701 Morrisette Drive, Springfield, Virginia 22152.

**SUPPLEMENTARY INFORMATION:** The Attorney General has delegated her authority under the Controlled Substances Act to the Administrator of the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority to exercise all necessary functions with respect to the promulgation and implementation of 21 CFR part 1301, incident to the registration of manufacturers, distributors, dispensers, importers, and exporters of controlled substances (other than final orders in connection with suspension, denial, or revocation of registration) has been redelegated to the Deputy Assistant Administrator of the DEA Office of Diversion Control (“Deputy Assistant Administrator”) pursuant to section 7 of 28 CFR part 0, appendix to subpart R.

In accordance with 21 CFR 1301.34(a), this is notice that on October 9, 2015, Myoderm, 48 East Main Street, Norristown, Pennsylvania 19401 applied to be registered as an importer of the following basic classes of controlled substances:

Controlled substance	Schedule
Amphetamine (1100) .....	II
Lisdexamfetamine (1205) .....	II
Methylphenidate (1724) .....	II
Pentobarbital (2270) .....	II
Nabilone (7379) .....	II
Codeine (9050) .....	II
Oxycodone (9143) .....	II
Hydromorphone (9150) .....	II
Hydrocodone (9193) .....	II
Levomethorphan (9210) .....	II
Meperidine (9230) .....	II
Methadone (9250) .....	II
Methadone intermediate (9254) ...	II
Morphine (9300) .....	II
Oxymorphone (9652) .....	II
Fentanyl (9801) .....	II

The company plans to import the listed controlled substances in finished dosage form for clinical trials, research, and analytical purposes.

The import of the above listed basic classes of controlled substances will be granted only for analytical testing, research, and clinical trials. This authorization does not extend to the import of a finished FDA approved or non-approved dosage form for commercial sale.

Dated: January 4, 2016.

**Louis J. Milione,**

*Deputy Assistant Administrator.*

[FR Doc. 2016-00213 Filed 1-8-16; 8:45 am]

**BILLING CODE 4410-09-P**